A2A Pharmaceuticals, Inc.'s Form 4 filing

Biomea Fusion, Inc. (BMEA) · filed May 10, 2023

Accession no.: 0001859061-23-000005
Filed: May 10, 2023
Trade date: May 8-9, 2023
Filing delay: 2 days
Rule 10b5-1 plan: Not checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $8.57M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
A2A Pharmaceuticals, Inc.CIK 0001859061	10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
May 8, 2023	Common Stock	SSaleDisposed	−100,000	$33.99^F1	−$3,399,000	3,800,000	Direct
May 9, 2023	Common Stock	SSaleDisposed	−150,000	$34.50^F2	−$5,175,000	3,650,000	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

A total of 100,000 shares were sold at an average price of 33.9931 in multiple transactions in a range of 33.01 to 34.855. Details of the specific transactions are available upon request.

Referenced by the price of 1 transaction in Table I.

A total of 150,000 shares were sold at an average price of 34.508 in multiple transactions in a range of 33.61 to 35.64. Details of the specific transactions are available upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)